健脾益气活血解毒法治疗难治性膜性肾病1例报告
A Case Report of Refractory Membranous Nephropathy Treated by the Method of Invigorating Spleen, Benefiting Qi, Activating Blood and Removing Toxicity
扫 描 看 全 文
1.上海中医药大学附属龙华医院肾病科,上海 200032
扫 描 看 全 文
鲁珍珍, 邓跃毅. 健脾益气活血解毒法治疗难治性膜性肾病1例报告[DB/OL].(2023-04-27)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=35868911&Fpath=home&index=0
LU Zhenzhen, DENG Yueyi. A Case Report of Refractory Membranous Nephropathy Treated by the Method of Invigorating Spleen, Benefiting Qi, Activating Blood and Removing Toxicity[DB/OL].(2023-04-27)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=35868911&Fpath=home&index=0
鲁珍珍, 邓跃毅. 健脾益气活血解毒法治疗难治性膜性肾病1例报告[DB/OL].(2023-04-27)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=35868911&Fpath=home&index=0 DOI:
LU Zhenzhen, DENG Yueyi. A Case Report of Refractory Membranous Nephropathy Treated by the Method of Invigorating Spleen, Benefiting Qi, Activating Blood and Removing Toxicity[DB/OL].(2023-04-27)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=35868911&Fpath=home&index=0 DOI:
病史摘要,2,患者2014年6月无明显诱因出现双下肢浮肿,未予重视。2014年9月再次出现双下肢水肿,查尿蛋白2+,肌酐40 μmol/L左右,予利尿及降压治疗后症情好转。为明确诊断,患者于2014年10月8日于上海交通大学医学院附属新华医院行肾穿刺活检,结果示:膜性肾病Ⅱ期。经强的松联合环孢素抑制免疫,症状未见明显缓解,遂于2015年2月改为吗替麦考酚酯联合强的松治疗,患者自诉复查肾功能在正常范围(具体报告未见),尿蛋白较前减少,2016年停用强的松,吗替麦考酚酯减量至250 mg bid po。2017年4月复查24 h尿蛋白为1.3 g,改为他克莫司2 mg tid治疗,症情较前缓解,肌酐维持在67~90 μmol/L之间,他克莫司逐渐减量。2017年6月24 h尿蛋白转阴(25.65 mg/24 h)。2019年2月,患者因症情缓解停用他克莫司治疗,后再次出现双下肢水肿及泡沫尿,且逐渐加重,2019年4月18日查24 h尿蛋白7669.38 mg,白蛋白27.8 g/L,肌酐63 μmol/L,为求中医药治疗多次于我科门诊及住院治疗。本次发病以来,患者无恶寒发热,无胸闷气急,无尿频、尿急、尿痛,无肉眼血尿,无皮疹关节痛,近期体重无明显减轻。中医诊断 水肿(脾虚湿热证)西医诊断 膜性肾病Ⅱ期;慢性肾脏病2期;高血压病3级(极高危)干预措施 予络活喜控制血压,阿托伐他汀调脂稳斑,速碧林抗凝,百奥、肝素、尿激酶抗凝降纤,兰索拉唑胶囊抑酸护胃,黄芪针益气消肿,配合中药健脾消肿方益气健脾。疗效转归 痊愈,未复发。
Summary of case history, In June 2014, the patient developed edema of both lower limbs without obvious inducement, which was ignored by the patient. In September 2014, edema of both lower limbs occurred again. Examination showed urinary protein 2+,and creatinine about 40 μmol/L. In order to confirm the diagnosis of the disease, renal biopsy was performed on October 5, 2014, which showed membranous nephropathy stageⅠ-Ⅱ. Prednisone combined with cyclosporine A was given, but the symptoms were not significantly relieved. In February 2015, the patient was changed the treatment of mycophenolate combined with prednisone. The examination showed that creatinine was within the normal range and the urine protein was reduced. In 2016, prednisone was discontinued and mycophenolate was reduced to 250mg bid. In April 2017, 24h urine protein was 1.3g, and the patient was changed to tacrolimus 2mg tid. The symptom was relieved, and the creatinine was maintained between 67-90 μmol/L. The dose of tacrolimus was gradually reduced, and the 24h urinary protein was 25.65mg in June 2017. The tacrolimus treatment was stopped in February 2019 due to the remission of symptoms. The patient developed edema of both lower limbs again, which gradually worsened. On April 18, 2019, the 24-hour urinary protein was 7669.38 mg, albumin was 27.8 g/L, and creatinine was 63 μmol/ L. The patient was admitted to our department for further traditional Chinese medicine treatment. Since the onset of the disease, the patient had no fever, chest tightness, shortness of breath, frequent urination, urgency and pain, gross hematuria, rash and joint pain, and no significant weight loss.,TCM diagnosis, Edema(spleen deficiency and dampness-heat syndrome),Western medicine diagnosis, Membranous nephropathy stage II; Chronic Kidney Disease stage 2; Hypertension stage 3( very high risk),Therapeutic methods, The treatment included controlling blood pressure, regulating lipid and stabilizing spots, anticoagulation and reducing fibrin, inhibiting gastric acid and protecting stomach, combined with astragalus for replenishing qi and reducing swelling, prescription of Jianpi Xiaozhong for strengthening spleen and reducing swelling injection.,Clinical outcomes, Cured without recurrence
膜性肾病健脾益气活血解毒【适合阅读专业】 肾脏病学中医学
Membranous nephropathyInvigorating spleenBenefiting qiActivating blood and removing toxicity【Suitable majors】 NephrologyTraditional Chinese medicine
Zhang Y, Jin Y, Guan Z, et al. The Landscape and Prognosis Potential of the T-Cell Repertoire in Membranous Nephropathy.[J] .Front Immunol, 2020, 11: 387. doi.org/10.3389/fimmu.2020.00387.
Glassock R. Diagnosis and natural course of membranous nephropathy[J]. Seminars in Nephrology, 2003, 23(4):324-332.
Chen M , Wang H Y , Li H , et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial[J]. American Journal of the Medical Sciences, 2010, 339(3):233.
Howman A , Chapman T L , Langdon M M , et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial[J]. Lancet, 2013, 381(9868): 744-751.
刘宝利,钟逸斐,刘伟敬,等.中医药临床优势病种探讨——膜性肾病[J].中国实验方剂学杂志,2021,27(16):185-190.
刘宝利,赵进喜,刘玉宁,等.论膜性肾病的中医概念与中医药治疗[J].北京中医药,2019,38(3):195-199.
蔡小凡,张晓丹,李雪玲,等. 中医方案治疗伴肾病范围蛋白尿的特发性膜性肾病的疗效分析[J]. 现代中西医结合杂志, 2020, 29(32):7.
0
浏览量
7
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构